YK11: Mechanism, Injectable Framing, and CNS Safety
Partial AR agonist with no human trials — mechanism, reported injectable bands, and preclinical neurotoxicity. Reference only.
YK11 is an experimental, non-approved steroidal SARM with very limited human evidence. The strongest data are preclinical: partial androgen receptor (AR) agonism with gene-selective activity, plus rat hippocampus studies raising neurological safety concerns rather than establishing clinical benefit. This article covers mechanism, injectable use framing from experience reports, reported dosing bands, CNS risk, and what to monitor. Educational reference only — not medical advice. For quick ranges and side lists, see the YK11 compound guide in cycle references.
What YK11 is
YK11 — (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester — is marketed as a myostatin inhibitor and grouped with selective androgen receptor modulators (SARMs). Oral capsules exist in the gray market, but the framing here centers injectable use because that is where the supplied experience reports and harm signals concentrate. No human clinical trial of injectable YK11 establishing safe muscle-mass increases appears in the reviewed literature.
- Non-approved for human use; scarce metabolism and safety data
- Partial AR agonist — not a full androgen like testosterone or trenbolone
- Gene-selective transcriptional effects in vitro, not uniformly androgen-like
- Preclinical safety signals outweigh efficacy evidence
Mechanism
YK11's pharmacology is best understood as competitive AR binding with weak downstream activation — a profile that explains both the muscle-partitioning theory and the CNS liability.
Partial agonist activity
In an ARE-luciferase assay, YK11 was active at sub-micromolar concentrations but reached only 10–20% of DHT's maximal reporter activity (Kanno et al., 2011). It is a partial agonist, not a full AR activator.
Gene-selective transcription
In MDA-MB-453 cells, YK11 induced FKBP51 and FGF18 similarly to DHT, induced HSD11B2 more weakly, and did not induce SARG. Transcriptional effects are selective — not a blanket androgen signal.
AR nuclear translocation without N/C interaction
YK11 accelerated AR nuclear translocation but did not induce the receptor's amino/carboxyl-terminal (N/C) interaction. It also inhibited DHT-mediated N/C interaction — leading the original authors to suggest SARM-like behavior rather than classical androgen agonism.
DHT displacement
YK11 binds AR competitively, displacing DHT from occupied receptors, then activates those receptors weakly. In muscle tissue this is sometimes framed as favorable — less full androgenic drive. In brain, prostate, and other DHT-dependent tissues the same mechanism is a liability: endogenous DHT is knocked off and replaced with a partial agonist. Experience reports describe CNS load comparable to heavy 19-nor exposure, with heavy hypothalamic AR binding flagged as a contributing factor.
Myostatin inhibition / nutrient partitioning (hypothesis)
YK11 is marketed and discussed as a myostatin inhibitor opening a novel growth pathway. Better nutrient partitioning and caloric flexibility at maintenance are commonly cited benefits in experience reports. This remains mechanistic theory — not an established human outcome in controlled data.
What people run it for
YK11's appeal in physique communities is as a plateau tool and partitioning aid — not a mass builder on par with classic injectables.
- Breaking plateaus when progress has stalled on a conventional stack
- Nutrient partitioning — eating more at maintenance without proportional fat gain (reported)
- Caloric flexibility during recomp or lean-gain phases
- Explicitly not a site-enhancement compound — do not expect localized growth from injection site
Injectable practical framing
Injectable YK11 is pinned on a daily schedule in experience reports. It does not behave like an injectable oral that must be timed pre-workout — effects are systemic, not acute pre-session pumps.
- Daily pinning is the common schedule in reported protocols
- Transient irritability 1–2 hours post-injection is commonly reported — plan around it
- Not pre-workout-dependent — pinning time is flexible relative to training
- CNS effects can accumulate over days; titration pace matters more than pin timing
Reported dosing bands
All figures below are experience reports only — not clinical dosing guidance. The literature does not establish a safe human dose for injectable YK11.
- Reported floor: ~10 mg/day (source notes 8.9 mg as a calculated minimum; 10 mg is the practical starting point in reports)
- Reported ceiling: ~50 mg/day in experienced users
- Titrate +10 mg only after a clear plateau — not on a fixed calendar schedule
- Deploy at a plateau rather than as a front-loaded kickstart in reported framing
Megadose failure modes (harm reduction)
Experience reports at 100–200 mg/day describe intolerance and inability to continue. A single-day gram exposure reportedly produced multi-day CNS recovery needs, persistent headache, and week-plus washout before feeling normal. These are documented failure modes — not dose exploration targets. The partial-agonist + CNS AR binding profile makes dose escalation especially punishing above modest bands.
CNS and neuro safety
CNS load is the primary safety concern — supported by both experience reports and preclinical rat data. Injectable YK11 is described in community pharmacology as neurotoxic in severity comparable to trenbolone at equivalent subjective tolerance thresholds, with hypothalamic AR binding highlighted as a mechanism of concern.
Rat hippocampus — oxidative stress and mitochondria
A five-week YK11 protocol at 0.35 g/kg in rats increased hippocampal oxidative stress and impaired mitochondrial function markers (Dahleh et al., 2023). Exercise partly offset some mitochondrial markers but did not reverse YK11-related oxidative stress or respiratory-chain impairments.
Rat hippocampus — neurochemistry and memory
YK11 showed modeled brain permeability. At anabolic-equivalent exposure it altered hippocampal neurochemistry, downregulated BDNF/TrkB/CREB signaling, increased IL-1β and IL-6, reduced IL-10, and activated apoptotic pathways (Dahleh et al., 2024). Memory consolidation was impaired — challenging the perception that SARMs carry minimal neurological risk.
Functional markers to track
Labs alone will not catch early CNS intolerance. Track sleep quality, irritability, headache severity, anxiety, cognitive fog, and training recovery alongside standard panels. If symptoms escalate with dose, the correct response is reduction or cessation — not adding ancillaries to push through.
Blood markers and monitoring
Human lab data for injectable YK11 are essentially absent. Use standard cycle monitoring as a baseline, with extra attention to functional neuro markers.
Hormones
Endogenous testosterone suppression is expected from AR agonism. LH/FSH and total/free T should be on the panel if running YK11 alongside or instead of a test base.
Lipids
HDL suppression is plausible given AR engagement, though magnitude is uncharacterized in humans. Trend lipids if available.
Liver
Injectable YK11 is not a 17α-alkylated oral — direct hepatotoxicity is less likely than with oral SARMs. Liver enzymes may still move from training, carrier oil, or indirect stress; trend ALT/AST/GGT on longer runs.
Kidney / cardiovascular
No specific YK11 kidney signal in the reviewed literature. Standard blood pressure and kidney marker trending (creatinine, BUN, eGFR) applies — see kidney-markers-hydration for draw context.
Detection
Relevant for tested athletes. A doping-control metabolism study identified 14 urinary metabolites after labeled YK11 administration, with no intact YK11 observed in urine (Piper et al., 2018).
- Unconjugated metabolites cleared within 24 hours
- Glucuronidated and sulfated metabolites remained detectable for more than 48 hours
- Three solid-state polymorphs exist (Turza et al., 2022) — relevant to product characterization, not clinical efficacy
Literature touchpoints
Named references from the reviewed preclinical and analytical literature.
- Piper T et al. (2018) — in vivo metabolism of SARM YK11; 14 urinary metabolites for doping controls. Drug Test Anal. doi:10.1002/dta.2527
- Kanno Y et al. (2011) — YK11 as partial AR agonist; 10–20% DHT max activity; gene-selective induction. Biol Pharm Bull. doi:10.1248/bpb.34.318
- Dahleh M et al. (2023) — YK11 oxidative stress and mitochondrial dysfunction in rat hippocampus. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.2023.106364
- Dahleh M et al. (2024) — YK11 hippocampal function: in silico, in vivo, ex vivo; memory consolidation impairment. Chem Biol Interact. doi:10.1016/j.cbi.2024.110971
- Turza A et al. (2022) — YK11 polymorphism (three solid-state forms). J Mol Struct. doi:10.1016/j.molstruc.2022.134281
What this article does not do
It does not establish injectable YK11 as safe or effective in humans. It does not prescribe doses — reported bands are experience-only. It does not replace clinical risk assessment for neurological, hormonal, or cardiovascular decisions. It does not validate megadose exploration.
The bottom line
YK11 is a partial AR agonist with weak human benefit evidence and meaningful preclinical neuro harm signals. DHT displacement makes CNS and DHT-dependent tissue exposure a first-class concern — not a footnote. Experience reports point to modest daily injectable bands with steep CNS penalties above them. If used at all, keep exposure conservative, runs short, and treat neuro symptoms as stop signals. For quick reference ranges, see the YK11 compound guide.
Educational reference only — not medical advice. Consult a qualified clinician before making health or protocol decisions.